HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates

Blood

Volumn 90, Issue 1, 1997, Pages 290-297

  Mannering, S I ^a   McKenzie, J L ^a   Fearnley, D B ^a   Hart, D N J ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD4 ANTIGEN; EPITOPE; HLA DR1 ANTIGEN; PEPTIDE;

ANTIGEN PRESENTING CELL; ARTICLE; CELL LYSATE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0030946078     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.290     Document Type: Article

References (29)

1. Kolb H, Schattenburg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Neiderwieser D, van Rhee F, Mittermueller J, de Titte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
2. Hill GR, Hart DNJ, Moore AF, Morris CM: Donor leukocyte infusions in the treatment of chronic myeloid leukaemia in relapse post bone marrow transplantation. Pathology 28:51, 1996
3. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 82:2273, 1993
4. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
5. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 82:691, 1993
6. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315:550, 1985
7. Kurzock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990, 1988
8. Ben-Neriah Y, Daley GQ, Mes-Masson A, Witte ON, Baltimore D: The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233:212, 1986
9. Chen W, Peace DJ, Rovira DK, You S, Cheever MA: T-cell immunity to the joining region of p210 bcr-abl protein. Proc Natl Acad Sci USA 89:1468, 1992
10. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukaemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680, 1995
11. Greco G, Fruci D, Accapezzato D, Barnaba V, Nisini R, Alimena G, Montefusco E, Vigneti E, Butler R, Tanigaki N, Tosi R: Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 10:693, 1996
12. BCR-ABL protein by human T cells. Leukemia 9:1344, 1995
13. + T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 88:3522, 1996
14. Pawelec G, Max H, Halder T, Bruserud O, Merl A, da Silva P, Kalbacher H: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118, 1996
15. Honda H, Fujii T, Takatoku M, Mano H, Witte ON, Yazaki Y, Hirai H: Expression of p210 bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85:2853, 1995
16. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukaemia in bcr/abl transgenic mice. Nature 344:251, 1990
17. Williams L, Egner W, Hart DNJ: Isolation and function of human dendritic cells. Int Rev Cytology 153:41, 1994
18. Young JW, Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7, 1996
19. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engelman EG, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52, 1996
20. Hock BD, Starling GC, Daniel PB, Hart DNJ: Characterisation of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology 83:573, 1994
21. McLellan AD, Starling GC, Hart DNJ: Isolation of human blood dendritic cells by Nycodenz discontinuous gradient centrifugation. J Immunol Methods 184:81, 1995
22. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321, 1975
23. Martin P, Papayannopoulou T: HEL cells: A new human erythroleukaemia cell line with spontaneous and induced globin expression. Science 216:1233, 1982
24. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 81:1369, 1993
25. Viner NJ, Nelson CA, Deck B, Unanue ER: Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. J Immunol 156:2365, 1996
26. Dermine S, Bertazzoli C, Marchesi E, Ravagnani F, Blaser K, Corneo GM, Pogliani E, Parmiani G, Gambacorti-Passerini C: Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-a hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 2:593, 1996
27. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Schienberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587, 1996
28. Coleman S, Perera P, Fisher J, Hoy T, Burnett AK, Lim SH: Abnormal TCR Vβ repertoire in patients with chronic myeloid leukaemia. Br J Haematol 90:358, 1995
29. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Eng J Med 327:1236, 1992